Central dogma: The clinical view

makes it clear that any form of current classical one-by-one gene status assessment will not be adequately informative to assess an actual patient's genetic risks.

Written bySteven Evans
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

From the point of view of patient care, your recent debate over classical genetics123 makes it clear that any form of current classical one-by-one gene status assessment will not be adequately informative to assess an actual patient's genetic risks.

Before there were tests to identify specific genetic mutations, cancer geneticists relied primarily on cancer family pedigrees, and interrelated family pedigrees, to suggest the cancer-risk status of an individual. These interconnected family cancer pedigrees were in effect a dynamic system-wide read-out of the outcome cancer-risk status of that individual, accommodating the actual vast variability and uncertainty inherent in the genetic expression as Goodman et al. have outlined.2 Remarkably this old corpus of interconnected family pedigree information may be just the "new" data form we seek to address the recognized enormous complexity, if not molecular uncertainty, in an individual's genetic profile.

We have demonstrated that one can apply a normative-model-driven form of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies